Sandoz delivers a comprehensive, high-quality portfolio and pipeline of oncology injectables, which go a step beyond standard generics. We have a broad portfolio of 25+ products and a robust pipeline that address the needs of traditional chemotherapy – the backbone of cancer treatment. By further growing our portfolio and strengthening our global presence, Sandoz will ensure that patients worldwide have greater access to a comprehensive range of these vital quality medicines at an affordable cost.
(Image source: IMS and Sandoz internal data)
The standard oncology injectables market is sizable. According to IMS Health and Sandoz estimates, annual global sales of standard oncology injectables (branded and generic) were estimated at about USD 24 billion in 2013. Unlike with traditional generics, the overall market for older mature products is also expected to grow due to the increasing prevalence of the disease, and as chemotherapy continues to remain the leading therapy.
What Makes Oncology Injectables Special?
Oncology injectable medicines are a highly specialized class of product and are difficult to produce due to their toxic characteristics and need for special preparation and handling. As a result, competing in this segment calls for significant capital outlays and investment in dedicated development and production capabilities, which ensure highly sterile environments and the containment of the raw material and product at every stage of the development and production process.
Sandoz already has a fully equipped development site for the development of the cytostatic injectables based in Unterach, Austria, which meets the rigorous quality standards of leading health and regulatory authorities worldwide. Production capacity and capabilities span several classes that include vials, ampoules and pre-filled syringes. Sandoz has also invested significantly in new technologies and capacity, including a new state-of-the-art facility for the production of pre-filled syringes, that allow us to offer global supply.